Ironwood Pharmaceuticals

IRWDPhase 3

Ironwood Pharmaceuticals is a commercial-stage biotech with a singular focus on gastrointestinal health, leveraging deep GI expertise to redefine the standard of care. Its flagship product, LINZESS, is a blockbuster GC-C agonist for IBS-C and CIC, establishing the company's commercial foundation. The company's strategic direction involves expanding its pipeline through targeted acquisitions, like VectivBio for apraglutide, to address severe GI conditions with high unmet need, such as Short Bowel Syndrome with intestinal failure (SBS-IF).

Market Cap

$495.7M

Focus

Small Molecules

IRWD · Stock Price

USD 3.049.41 (-75.58%)

Historical price data

AI Company Overview

Technology Platform

Pioneering expertise in guanylate cyclase-C (GC-C) agonist development, creating orally available peptides that target intestinal receptors. Also developing a platform of long-acting GLP-2 analogs for intestinal growth and absorption.

Pipeline Snapshot

33 drugs in pipeline, 11 in Phase 3

Drug	Indication	Stage
Linaclotide	Irritable Bowel Syndrome With Constipation	Approved
Linaclotide + Placebo	Irritable Bowel Syndrome Characterized by Constipation	Approved
Linaclotide + Matching Placebo	Chronic Idiopathic Constipation	Phase 3
Linaclotide 290 micrograms + Linaclotide 145 micrograms + Matching placebo	Chronic Constipation	Phase 3
Linaclotide	Irritable Bowel Syndrome With Constipation	Phase 3

Opportunities

Significant opportunity exists in expanding the apraglutide franchise into pediatric SBS-IF and other severe malabsorptive GI conditions.

The company's focused GI expertise also allows for targeted in-licensing or acquisition of additional mid-to-late-stage GI assets to further diversify its revenue base beyond LINZESS.

Risk Factors

Key risks include clinical trial failure or regulatory delays for apraglutide, its lead pipeline asset.

The company also faces long-term patent exclusivity risks for its blockbuster product, LINZESS, and intense competition in both the functional and severe GI therapeutic markets.

Competitive Landscape

In functional GI disorders, LINZESS competes with Trulance and Amitiza. In SBS-IF, the main competitor is teduglutide (Gattex/Revestive). Ironwood differentiates through its integrated, GI-specialized model, deep patient journey insights, and focus on developing therapies with meaningful efficacy and dosing advantages.

Publications

Patents

Pipeline